Biota Pharmaceuticals Appoints Armando Anido and Michael Dunne, M.D. to Its Board of Directors
September 22 2015 - 7:00AM
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a
biopharmaceutical company focused on the discovery and development
of direct-acting antivirals to treat infections that have limited
therapeutic options, today announced the appointments of Armando
Anido and Michael Dunne, M.D. to its Board of Directors. Both of
these new directors will begin serving immediately and will stand
for election for a full one-year term at the Company's Annual
Meeting of Stockholders in November 2015.
"It is with great pleasure that we welcome both Armando and Mike
to our Board of Directors. Their collective success and leadership
in the development and commercialization of infectious disease
products will be invaluable to us as we continue to advance our
clinical-stage pipeline of direct-acting antivirals," commented
Joseph M. Patti, PhD, President and Chief Executive Officer at
Biota.
Mr. Anido has served as Chairman of the Board and Chief
Executive Officer of Zynerba Pharmaceuticals since October 2014.
Prior to joining Zynerba, he served as Chief Executive Officer and
director of NuPathe, Inc. from 2012 through its acquisition by Teva
Pharmaceuticals in 2014, during which time he led the company
through FDA approval of its lead product, Zecuity,
a transdermal patch for migraine. From 2006 to 2011, Mr. Anido
served as Chief Executive Officer and President and as a director
of Auxilium Pharmaceuticals, Inc., a specialty
pharmaceutical company acquired in 2015 by Endo International
plc. Prior to that, he served as Executive Vice President, Sales
and Marketing at MedImmune, Inc. and played a major role in the
commercialization of Synagis®, a monoclonal antibody approved for
the prevention of respiratory syncytial infections in infants.
Before joining MedImmune, Mr. Anido served in a series of positions
with increasing responsibility at Glaxo Wellcome, Inc., including
Director, HIV Marketing and Vice President, Central Nervous System
Marketing. He holds an M.B.A. and a B.S. in Pharmacy from West
Virginia University.
Dr. Dunne is currently Chief Science Officer of Iterum
Pharmaceuticals plc. From 2014 to 2015, Dr. Dunne was Vice
President Research and Development at Actavis plc (now Allergan
plc). Prior to its acquisition by Actavis plc in 2014, Dr. Dunne
served as the Chief Medical Officer at Durata Therapeutics, during
which time he led the clinical development of dalbavancin, an
intravenous antibiotic for the treatment of gram-positive
infections. Prior to joining Durata in 2009, Dr. Dunne worked at
Pfizer for 17 years, which included holding positions of Vice
President, Therapeutic Area Development and Head, Infectious
Diseases, Global R&D and, subsequent to that, Vice President,
Portfolio Policy, Worldwide Policy & Public Affairs, Global
R&D. During his time at Pfizer, Dr. Dunne led the clinical
development of a number of infectious diseases products, including
maraviroc, voriconazole, and Zithromax®. Dr. Dunne currently sits
on the scientific advisory committee for the Global Alliance for TB
Drug Development and the Medicines for Malaria Venture. Dr. Dunne
holds an M.D. from the State University of New York Health Science
Center at Brooklyn, completed his residency in Internal Medicine as
well as fellowships in pulmonary medicine and infectious diseases
at Yale University and has a B.A. in Economics from Northwestern
University.
The Company also announced that Dr. James Fox will not stand for
re-election to its Board of Directors at its Annual Meeting of
Shareholders in November 2015.
"We certainly understand Jim's desire to reduce his significant
travel, business and board commitments at this time. On behalf of
Biota and our board, I want to thank Jim for being instrumental in
the challenging transition of the organization and being supportive
of the implementation of our strategy over the past several years
to better position us for future success," said Russell Plumb,
Executive Chairman of Biota Pharmaceuticals, Inc.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and
development of direct-acting antivirals to treat infections that
have limited therapeutic options and affect a significant number of
patients globally. The Company has four product candidates in
clinical development. These include vapendavir, an oral treatment
for human rhinovirus infections in moderate-to-severe asthmatics
that is currently being evaluated in the Company's ongoing Phase 2b
SPIRITUS trial; BTA074, a topical antiviral treatment in Phase 2
development for genital warts caused by human papillomavirus types
6 & 11; BTA585, an oral fusion (F) protein inhibitor in Phase 1
development for the treatment of respiratory syncytial virus (RSV)
A & B infections; and laninamivir octanoate, a one-time,
inhaled treatment in Phase 2 development for influenza A and B
infections. The Company also has a preclinical stage RSV non-fusion
inhibitor program. For additional information about the Company,
please visit www.biotapharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve known and unknown risks and uncertainties concerning
Biota Pharmaceuticals, Inc. business, operations and financial
performance. Any statements that are not of historical facts may be
deemed to be forward-looking statements. Other cautionary
statements contained elsewhere in this press release and in the
Company's Annual Report on Form 10-K for the year ended June 30,
2015, as filed with the U.S. Securities and Exchange Commission on
September 11, 2015. There may be events in the future that the
Company is unable to predict, or over which it has no control, and
the Company's business, financial condition, results of operations
and prospects may change in the future. The Company may not update
these forward-looking statements more frequently than quarterly
unless it has an obligation under U.S. Federal securities laws to
do so.
Biota is a registered trademark of Biota Pharmaceuticals,
Inc.
CONTACT: Joseph M. Patti, PhD
President and Chief Executive Officer of Biota
(678) 221-3352
j.patti@biotapharma.com
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024